1. Overview
The analysis of chromosomes 3, 7, 17, and the 9p21 locus using multi-target fluorescence in situ hybridization (FISH) is an established molecular method for the diagnosis of bladder cancer from voided urine specimens. This non-invasive diagnostic approach detects chromosomal abnormalities commonly associated with urothelial carcinoma.
The multi-target FISH assay employs probes directed against the centromeric regions of chromosomes 3, 7, and 17, along with the 9p21 locus, which harbors tumor suppressor genes. Cytospin preparations from voided urine samples are used for analysis.
Studies have demonstrated high detection rates, with polysomies of chromosomes 3, 7, and 17 detected in 84.0%, 48.0%, and 78.0% of cases, respectively, and deletion of the 9p21 gene observed in approximately 80.0% of cases. These chromosomal alterations are strongly associated with bladder cancer and support the clinical utility of this assay. Chromosomes-3-7-17-and-9p21
2. Symptoms
Patients undergoing testing for chromosomal abnormalities of 3, 7, 17, and 9p21 often present with symptoms suggestive of bladder pathology. Common clinical symptoms include painful micturition, gross or microscopic hematuria, frequent urination, pain or burning sensation during urination, a persistent feeling of needing to urinate despite an empty bladder, and nocturia.
These symptoms raise clinical suspicion for bladder cancer and warrant further investigation using cytogenetic and molecular diagnostic methods such as FISH analysis on urine samples.
3. Causes
Chromosomal abnormalities detected by this assay are primarily caused by the malignant transformation of urothelial cells. Polysomy of chromosomes 3, 7, and 17 reflects increased chromosomal copy numbers, while deletion of the 9p21 locus indicates loss of tumor suppressor gene regions.
These genetic alterations are characteristic of bladder cancer and contribute to abnormal cell proliferation, impaired cell cycle regulation, and tumor progression. The data presented in the reference studies are derived from published literature and are included to provide basic information regarding signal interpretation and cutoff values for FISH positivity.
4. Risk Factors
The presence of polysomies involving chromosomes 3, 7, and 17 and the deletion of the 9p21 locus is strongly associated with bladder cancer. Patients with persistent urinary symptoms, hematuria, or a prior history of urothelial malignancy are at increased risk of harboring these chromosomal abnormalities.
FISH-positive results are determined using optimal cutoff values based on the average percentage of cells with abnormal signal patterns in normal donor urine specimens. Exceeding these cutoff thresholds increases the likelihood of malignancy. The assay demonstrates high sensitivity and specificity, making it a valuable tool for identifying high-risk patients and detecting disease recurrence.
5. Prevention
While chromosomal abnormalities themselves cannot be prevented, early detection plays a crucial role in disease management. The use of multi-target FISH on voided urine samples offers a non-invasive method for early diagnosis and monitoring of bladder cancer.
Proper sample collection is essential for accurate results. A randomly voided urine specimen is sufficient, with a minimum of 50 ml collected in a sterile container. The sample should be centrifuged, and the pooled residue used for FISH analysis.
The high sensitivity and specificity of the FISH assay for chromosomes 3, 7, 17, and 9p21 may reduce the need for invasive diagnostic procedures such as cystoscopy in selected cases. Correlation of FISH results with clinical findings and other diagnostic modalities ensures accurate interpretation and optimal patient management.
